Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
458 Leser
Artikel bewerten:
(2)

Global Liver Institute: International NASH Day Highlights a Common - But Unfamiliar - Liver Disease

Finanznachrichten News

Global Liver Institute Convenes Communities Around the Globe Today to Reverse the Growing Trend of Fatty Liver Disease

Washington, D.C., June 08, 2022calls attention to NASH by leading the 5th annual International NASH Dayon June 9. The number of people with this advanced liver disease is expected to doubleby 2030, but NASHday aims to prevent this growth. Join the movement to StopNASHNow by listening inas 24 expert panelists from around the globe share the latest updates about the disease or adding to the conversation on social media (NASHday). The movement permeates the globe through many locally-organized events to educate about, screen for, and prevent NASH.

NASHof NASH and NAFLD around the world, and it is becoming the most common cause of liver disease. Given its widespread impact and the possibility of prevention in most cases of this disease, NASH emerges as a global health priority.

"With over a hundred million people worldwide already who have NASH and several times more in the earlier stages, people have reason to know about this progressive condition and what they can do today to combat it," shared Donna R. Cryer, president and CEO of GLI. "Collective action is imperative to be certain that individuals in each community, no matter their background or environment, are informed and equipped to prevent fatty liver disease. The momentum that we build together today must advance and sustain the global fight against NASH."

If you didn't know, then now you know! Even though NASH is common, it remains relatively unknown, leaving much work to be done to increase public awareness. This year, GLI and its partners join with the theme to StopNASHNow: Even as therapies for NASH are being developed, there are many steps that people and their doctors can take today to prevent, reverse, or slow the progression of fatty liver disease. For the 25% of adults already affected worldwide, it is due time for this life-changing knowledge.

  • An estimated 1 in 4 (https://pubmed.ncbi.nlm.nih.gov/26707365/) adults around the world already has NAFLD.
  • As many as 1 in 20 (https://pubmed.ncbi.nlm.nih.gov/26707365/) people has NASH.
  • The prevalence of NAFLD is increasing (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838529/) among all global regions and among all ethnicities in parallel with diabetes and obesity.
  • NASH can progress (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395802/#:~:text=Numerous studies have demonstrated that,in this group%5B7%5D) to cirrhosis or liver cancer - which may necessitate a liver transplant.

"International NASH Day demonstrates the potential that is realized as all stakeholders in NASH come together worldwide," said Jeff McIntyre, NASH Programs Director at GLI. "From in-person screenings in at-risk communities to educational materials in 16 languages to challenging conversations with researchers, providers, and patients - today the world joins to create meaningful solutions for patients at every stage of NAFLD and NASH."

International NASH Day has garnered the endorsement of prominent organizations from around the globe: American Association for the Study of Liver Diseases (AASLD); Association of Black Gastroenterologists and Hepatologists (ABGH); Asociación Latinoamericana para el Estudio del Hígado (ALEH); Associazione Italiana Studio del Fegato (AISF); Asociación Mexicana de Hepatología (AMH); Asian Pacific Association for the Study of the Liver (APASL); Canadian Association for the Study of the Liver (CASL); Conference on Liver Disease in Africa (COLDA); European African Treatment Advocates Network (EATAN); European Fatty Liver Conference (EFLC); European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN); EU Patient-Centric Clinical Trial Platforms (EU-PEARL); Fondazione Epatocentro Ticino; Hepatology Society, Dhaka, Bangladesh; Hepatology Society of the Philippines (HSP); Indian National Association for the Study of the Liver (INASL); North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN); Sociedad Argentina de Hepatologia (SAHE);Turkish Association for the Study of the Liver (TASL); United European Gastroenterology (UEG); World Gastroenterology Organisation (WGO); and World Patients Alliance (WPA).

Get Involved

To view the expert panels throughout the day today, visit https://hopin.com/events/5th-annual-international-nash-day/registration. Panels are available in English, French, Hindi, Mandarin, and Spanish throughout the day.

For additional information on International NASH Day, visit www.international-nash-day.com.

Support the NASH Day social media campaign using hashtags NASHday StopNASHNow. Please direct any additional questions to NASHDay@globalliver.org.

International NASH Day and its logo are registered trademarks of Global Liver Institute.

# # #

About Global Liver Institute

Global Liver Institute,Facebook,Instagram,LinkedIn, andYouTube. GLI is the global host of International NASH Day.


© 2022 GlobeNewswire (Europe)
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.